A 79% confirmed objective response rate is the number Lilly needs the oncology community to sit with, because it comes from a platinum-sensitive ovarian cancer population that often carries prior PARP inhibitor exposure, where meaningful response rates are genuinely hard to deliver. That figure, paired with a 100% disease control rate, comes from the first clinical readout of sofetabart mipitecan (Sofe-M), Lilly’s FRα-targeting antibody-drug conjugate, now presented in combination with bevacizumab at ESMO 2026.
The two details that sharpen the result: activity held across FRα expression levels, and clinical benefit persisted in patients who had already received PARP inhibitors. Both matter because patient selection has been a recurring complication in the FRα-targeting space. If a drug requires high FRα expression to work, the eligible population shrinks. If prior PARP exposure blunts it, the drug arrives too late for the patients most likely to need it. Sofe-M, based on this early dataset, does not appear to carry either restriction, though the source does not specify the sample size or maturity of the data in a way that allows firm conclusions.
This is the first clinical dataset Lilly has disclosed for Sofe-M in platinum-sensitive disease specifically, so the figures reflect early-stage experience. The combination with bevacizumab, an anti-VEGF agent already used in ovarian cancer, adds a layer of complexity to interpreting how much each component contributes, and Lilly has not yet clarified that in the disclosed data. What the readout does establish is a clinical signal strong enough to anchor a development program in a setting where the company clearly wants to compete against established FRα-directed therapies.
The number to track from here is how the response rate holds as the dataset matures and follow-up extends, particularly whether durable responses translate into progression-free survival data that could support a registration-enabling design. A 79% ORR in a single-arm early cohort is encouraging; the question is whether disease control remains at 100% once a larger population with longer follow-up is in the mix.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
